Intra-Cellular Therapies, Inc. financial data

Symbol
ITCI on Nasdaq
Industry
Pharmaceutical Preparations
Location
135 Route 202/206, Suite 6, Bedminster, NJ
State of incorporation
DE
Fiscal year end
December 31
Former names
Oneida Resources Corp. (to 8/29/2013)
Latest financial report
10-Q - Q3 2024 - Oct 30, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 664 % -16.4%
Quick Ratio 12.2 % -68.3%
Debt-to-equity 18.4 % +9.92%
Return On Equity -9.93 % +60.2%
Return On Assets -8.38 % +60.7%
Operating Margin -105 % +69.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 106M shares +10.2%
Common Stock, Shares, Outstanding 106M shares +10.2%
Entity Public Float 6B USD
Common Stock, Value, Issued 11K USD +10%
Weighted Average Number of Shares Outstanding, Basic 106M shares +10%
Weighted Average Number of Shares Outstanding, Diluted 106M shares +10%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 250M USD +199%
Revenue from Contract with Customer, Excluding Assessed Tax 614M USD +46.1%
Research and Development Expense 217M USD +32.7%
General and Administrative Expense 471M USD +17.9%
Operating Income (Loss) -122M USD +29.6%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -85.1M USD +45.1%
Income Tax Expense (Benefit) 1.24M USD +559%
Net Income (Loss) Attributable to Parent -86.4M USD +44.3%
Earnings Per Share, Basic -0.87 USD/shares +46%
Earnings Per Share, Diluted -0.87 USD/shares +46%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 464M USD +367%
Accounts Receivable, after Allowance for Credit Loss, Current 146M USD +41.8%
Inventory, Net 23.5M USD -45.2%
Assets, Current 1.27B USD +81%
Property, Plant and Equipment, Net 2.01M USD +12.1%
Operating Lease, Right-of-Use Asset 14M USD +4.84%
Other Assets, Noncurrent 6.22M USD +7131%
Assets 1.32B USD +84.5%
Accounts Payable, Current 10.3M USD -2.59%
Liabilities, Current 166M USD +61.1%
Operating Lease, Liability, Noncurrent 13.5M USD -2.77%
Liabilities 180M USD +53.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.63M USD
Retained Earnings (Accumulated Deficit) -1.67B USD -5.44%
Stockholders' Equity Attributable to Parent 1.14B USD +90.6%
Liabilities and Equity 1.32B USD +84.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -34.1M USD +43.2%
Net Cash Provided by (Used in) Financing Activities 9.99M USD +174%
Net Cash Provided by (Used in) Investing Activities 16.2M USD
Common Stock, Shares Authorized 175M shares 0%
Common Stock, Shares, Issued 106M shares +10.2%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.95M USD +89.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 466M USD +361%
Deferred Tax Assets, Valuation Allowance 271M USD +22.8%
Operating Lease, Liability 17.7M USD +1.34%
Depreciation 132K USD -1.49%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -83.4M USD +44.8%
Lessee, Operating Lease, Liability, to be Paid 21.8M USD -3.29%
Property, Plant and Equipment, Gross 7.14M USD +12.2%
Operating Lease, Liability, Current 4.2M USD +17.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.51M USD +15.5%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.44M USD +17%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.09M USD -19.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.57M USD +15.1%
Deferred Tax Assets, Operating Loss Carryforwards 139M USD -17.7%
Unrecognized Tax Benefits 2.5M USD +47.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.71M USD +17%